Schrödinger

What Schrödinger does

Schr\u00f6dinger (NASDAQ:SDGR) is a computational molecular discovery software company founded in 1990 and headquartered in New York, with approximately 800 employees across 15 global locations. The company operates a dual business model. First, it licenses a physics-based computational platform that combines quantum mechanics (Jaguar), molecular dynamics (Desmond), molecular docking (Glide), free energy perturbation (FEP+), and proprietary force fields (OPLS4/OPLS3e) with machine learning capabilities (DeepAutoQSAR, LiveDesign ML, generative De Novo Design). The platform is delivered through Maestro (the GUI) and LiveDesign (enterprise informatics), and is transitioning from on-premise licensing to hosted cloud subscriptions with a target of 75% hosted mix within three years. Second, the company pursues co-founded drug discovery programs and strategic collaborations with major pharmaceutical companies, holding equity stakes in entities including Nimbus Therapeutics, Morphic Therapeutic (acquired by Lilly 2024), Ajax Therapeutics (acquired by Lilly 2026 for up to $2.3 billion), Structure Therapeutics, and Copernic Catalysts.

The platform serves three primary customer segments: pharmaceutical and biotechnology companies (the dominant segment with names including Eli Lilly, Novartis, Bristol Myers Squibb, Takeda, and Otsuka), academic research institutions, and materials science companies (specialty chemicals, electronics, energy). FY2025 total revenue was $255.9 million, with software revenue of $199.5 million (+10.6% YoY) and drug discovery revenue of $56.4 million (more than doubled YoY). The software business sells through direct enterprise field sales with annual contract value (ACV) as the key metric; 2026 software ACV guidance is $218-228 million, implying 10-15% growth. Drug discovery revenue flows from milestone and royalty payments on partnered programs, with cumulative potential milestone exposure estimated at approximately $5 billion across the collaboration portfolio.

The company's proprietary clinical pipeline includes SGR-1505 (MALT1 inhibitor with FDA Fast Track and Orphan Drug Designations for B-cell malignancies, Phase 1) and SGR-3515 (Wee1/Myt1 dual kinase inhibitor for solid tumors, Phase 1). Recent strategic moves include a multi-target Novartis collaboration worth up to $2.3 billion in potential milestones (2025), integration of Eli Lilly's TuneLab AI platform into LiveDesign (January 2026), a multi-year platform agreement with AI-native biotech Manas AI (January 2026), adoption of NVIDIA's BioNeMo Agent Toolkit (June 2026), and the planned summer 2026 launch of Bunsen, an agentic AI co-scientist system. As of January 2026, the company's valuation was approximately $4.74 billion with $402.3 million in cash and equivalents at year-end 2025.

Name

Schrödinger

Legal name

Schrödinger, Inc.

Website

https://schrodinger.com

Company type

Public

Founded year

1990

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Schr\u00f6dinger provides a physics-based computational molecular discovery platform combining quantum mechanics, molecular dynamics, and machine learning to accelerate drug discovery and materials science for pharmaceutical, biotechnology, academic, and materials industry customers, supplemented by equity stakes in co-founded therapeutic programs.

Ownership category

akta.pro rank

Product category

Computational Drug Discovery Software

NAICS

Software Publishers (5132), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Computational drug discovery
• Molecular simulation software
• Pharmaceutical research platforms
• Materials science modeling
• Quantum chemistry software

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Software Licensing: Recurring software licenses for computational molecular discovery platform. Schrödinger is transitioning from on-premise to hosted (cloud-based) software licensing model, targeting 75% migration within three years. Software revenue was $199.5 million in FY2025, growing 10.6% year-over-year.
2. Drug Discovery Collaborations: Milestone payments and collaboration revenue from drug discovery programs. Drug discovery revenue doubled to $56.4 million in FY2025. Includes partnerships with Lilly, Novartis, Bristol Myers Squibb, Otsuka, and others, with potential milestones up to $5 billion cumulative across portfolio.
3. Strategic Collaborations - Novartis: $150 million upfront payment from Novartis for multi-target research collaboration with up to $2.3 billion in potential milestone payments

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Schrödinger develops and licenses a physics-based computational molecular discovery platform combining quantum mechanics, molecular dynamics, and machine learning to accelerate drug discovery and materials science research. The platform centers on Maestro as the user interface, with computational engines including Glide (docking), FEP+ (free energy perturbation), Desmond (molecular dynamics), and Jaguar (quantum mechanics), integrated through the LiveDesign enterprise informatics environment. The company also co-develops proprietary therapeutics (SGR-1505, SGR-3515) and earns milestone/royalty revenue from collaborations with major pharmaceutical partners.

Product overview

Schrödinger offers a comprehensive computational molecular discovery platform combining physics-based simulation with AI/ML capabilities. The platform architecture centers on Maestro as the primary user interface, with core computational engines including Glide (docking), FEP+ (free energy calculations), Desmond (molecular dynamics), and Jaguar (quantum mechanics). LiveDesign serves as the enterprise informatics platform enabling collaborative workflows. AI/ML capabilities are delivered through DeepAutoQSAR (automated QSAR modeling), LiveDesign ML, and MS Informatics for materials applications. The platform serves both Life Sciences (drug discovery) and Materials Science sectors, and Schrödinger advances proprietary therapeutics through clinical programs including SGR-1505 (MALT1 inhibitor) and SGR-3515 (Wee1/Myt1 inhibitor) in Phase 1 trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Maestro The primary graphical user interface for Schr\u00f6dinger's molecular modeling suite, providing comprehensive access to all computational tools for molecular discovery and design across life sciences and materials science applications. Targeted at computational chemists, medicinal chemists, and materials scientists.
• Glide Ligand-receptor molecular docking solution for virtual screening and binding mode prediction using extra-precision scoring to predict binding affinities and identify promising drug candidates. Used by pharmaceutical discovery teams for hit identification.
• FEP+ (Free Energy Perturbation) High-performance free energy calculation engine enabling accurate prediction of binding affinities and ranking of molecular candidates. Used for lead optimization in drug discovery programs.
• LiveDesign Enterprise informatics platform providing a digital molecular design lab for collaborative drug discovery, integrating AI models, physics-based calculations, and experimental data across life sciences and materials science. Targets multi-disciplinary research teams in pharmaceutical companies.
• BioLuminate Specialized module for biologics drug discovery providing computational tools for antibody design, protein-protein interaction analysis, and developability assessment for large molecule therapeutics. Targets biologics discovery teams.
• DeepAutoQSAR Automated machine learning solution for training and applying predictive QSAR/QSPR models based on molecular structure with automated hyperparameter optimization, ensemble methods, and uncertainty quantification. Used by computational chemists for property prediction.
• Desmond High-performance molecular dynamics simulation system for modeling organic and bioorganic molecules, enabling simulation of protein-ligand interactions and dynamic behavior of molecular systems. Used by both life science and materials science researchers.
• Jaguar High-performance quantum mechanics package for accurate prediction of molecular structures and properties using density functional theory and ab initio methods. Supports DFT functionals with dispersion corrections, solvent effects modeling, and automated workflows.
• MS LiveDesign Materials Science version of the LiveDesign enterprise informatics platform for collaborative materials design and optimization. Targets materials science teams in specialty chemicals, energy, and consumer packaged goods.
• MS Informatics Materials Science informatics module providing molecular featurization and machine learning tools for organic, organometallic, polymer, formulation, and inorganic materials. Combines physics-based featurization with automated ML workflows for property prediction.
• Modeling Services Expert computational science services leveraging Schr\u00f6dinger's platform to advance research projects through key drug discovery stages, providing a high-velocity entry point to the Schr\u00f6dinger platform. Targeted at biotech and pharma customers needing augmented computational capacity.
• SGR-1505 (MALT1 inhibitor) Proprietary Phase 1 clinical stage MALT1 protease inhibitor for treatment of relapsed or refractory B-cell lymphomas including chronic lymphocytic leukemia and Waldenstr\u00f6m macroglobulinemia. Received FDA Fast Track Designation and Orphan Drug Designation.
• SGR-3515 (Wee1/Myt1 inhibitor) Proprietary Phase 1 clinical stage Wee1/Myt1 dual kinase inhibitor for treatment of advanced solid tumors, leveraging synthetic lethality mechanism in cancer cells. Developed using Schr\u00f6dinger's computational platform.

Named customers7 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability10 records

Feature11 records

Partnerships

13 partnerships are on record, tiered major, core and minor.

• NVIDIAmajorTechnology or Integration · 23 June 2026Schrödinger is one of 50+ companies adopting NVIDIA's BioNeMo Agent Toolkit for life sciences AI agents spanning biology, chemistry, genomics, and drug discovery. Leverages NVIDIA's library of life sciences technologies including Nemotron, NemoClaw, and BioNeMo microservices.
• Eli LillycoreStrategic or Co-development Partner · 9 January 2026Schrödinger announced collaboration to integrate Lilly's TuneLab AI platform into Schrödinger's LiveDesign enterprise informatics platform, giving biotech companies priority access to TuneLab workflows. TuneLab uses federated learning to enable privacy-preserving collaboration. Schrödinger is a priority platform partner for TuneLab workflows in the biotech ecosystem.
• Manas AIcoreStrategic or Co-development Partner · 1 January 2026Multi-year agreement for Manas AI to access Schrödinger's physics-based computational drug discovery platform, integrating it with Manas AI's AI 'world model' for identifying diverse molecular binders. Deep integration combining Schrödinger's physics-based methods with Manas AI's machine learning capabilities.
• NovartiscoreStrategic or Co-development Partner · 1 January 2025Multi-target research collaboration with up to $2.3 billion in potential milestone payments. Novartis collaboration includes multiple undisclosed programs in discovery stage. $150 million upfront payment received.
• Otsuka PharmaceuticalmajorStrategic or Co-development PartnerCollaboration initiated December 2022 to discover novel medicines against undisclosed CNS targets. Schrödinger received undisclosed upfront payment and is eligible for additional milestones as program progresses.
• Bristol Myers SquibbmajorStrategic or Co-development PartnerCollaboration on undisclosed program in neurology. Schrödinger is progressing an undisclosed program for evaluation as potential treatment for pulmonary arterial hypertension with Lilly under separate collaboration.
• Nimbus TherapeuticscoreStrategic or Co-development PartnerMultiple collaborations including TYK2 inhibitor (TAK-279, acquired by Takeda with $111.3M distribution to Schrödinger), HPK1 inhibitor in Phase 1/2 for immuno-oncology, and JAK2 inhibitor (AJ1-11095, acquired by Lilly with Ajax acquisition).
• Bright Angel TherapeuticsminorStrategic or Co-development PartnerCollaboration on Hsp90 inhibitor design for antifungal applications. Schrödinger holds equity stake in Bright Angel Therapeutics.
• AnthropicmajorTechnology or IntegrationSchrödinger is listed as a major enterprise partner using Claude for healthcare and life sciences applications. Partnership enables AI-powered drug discovery workflows leveraging Anthropic's Claude AI platform.
• UCSFminorStrategic or Co-development PartnerPartnership with UCSF for AI-based drug design as part of computational biology market developments.
• Ajax TherapeuticscoreStrategic or Co-development PartnerCo-founded company in which Schrödinger holds approximately 6% equity. JAK2 inhibitor AJ1-11095 acquired by Lilly for up to $2.3 billion. Schrödinger eligible for milestones and royalties. Collaboration expanded July 2025 with additional JAK target.
• Structure TherapeuticscoreStrategic or Co-development PartnerCo-founded company in which Schrödinger holds equity stake. Collaborations include GLP-1R selective program for obesity (ACCG-2671 in Phase 1), APJR agonist for pulmonary arterial hypertension, LPA1R for idiopathic pulmonary fibrosis. Schrödinger eligible for milestones and low single-digit royalties.
• Copernic CatalystsminorStrategic or Co-development PartnerCollaboration on jointly-developed ammonia synthesis catalyst Neptune demonstrating over 2x ammonia yield of existing catalysts. Pilot demonstrations planned for 2026/27. Also working on more efficient ethylene oxide catalyst.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• OpenEye Scientific (Cadence Design Systems): OpenEye, owned by Cadence, builds molecular modeling and cheminformatics software (e.g., OMEGA, FRED, ROCS) for drug discovery and is the closest direct competitor to Schrödinger's Maestro/Glide/FEP+ stack for small-molecule computational chemistry.
• Chemical Computing Group (CCG / MOE): CCG sells the Molecular Operating Environment (MOE), one of the most widely deployed academic and industrial molecular modeling platforms; directly comparable in target customer, pricing model, and core functionality (docking, QSAR, protein modeling) to Schrödinger.
• Dotmatics: Dotmatics provides an enterprise scientific informatics platform (e.g., Studies, Geneious, SnapGene) for R&D workflows; competes with LiveDesign in collaborative drug discovery informatics and has been aggressively bundling cheminformatics capabilities.

Broad incumbents

• Dassault Systèmes BIOVIA: BIOVIA is Dassault Systèmes' life sciences scientific software suite covering molecular simulation, biologics, lab informatics, and regulatory; broad incumbent with overlapping capabilities (Discovery Studio, Materials Studio) competing with Schrödinger's life sciences and materials portfolios.
• Certara: Certara is a public biosimulation and drug development technology company (Phoenix, Simcyp, Synchrogenix); sells adjacent drug discovery and regulatory software plus services to the same pharmaceutical/biotech customer base as Schrödinger.

Emerging players

• Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab experimentation with AI/ML to drive drug discovery; overlaps with Schrödinger's pipeline-cofounder model and AI-driven discovery narrative but takes a data-first rather than physics-first approach.
• Insitro: Insitro uses ML on large-scale biological data to discover therapeutics, with strategic pharma partnerships (Lilly, Bristol Myers); competes for the same enterprise AI-for-drug-discovery mindshare and partnership dollars that drive Schrödinger's drug discovery revenue.
• Isomorphic Labs: Alphabet-owned Isomorphic Labs is building an AI-first drug discovery engine founded by DeepMind's protein-structure team; an emerging AI-native peer whose AlphaFold-anchored approach could compete with Schrödinger's physics-based methods for new partner deals.
• Exscientia: Exscientia pioneered AI-driven small molecule design and operates a hybrid AI + pharma partnership model; competes for both pipeline collaboration economics and the broader "AI for drug discovery" narrative that Schrödinger is leaning into with Bunsen and NVIDIA integrations.
• Atomwise: Atomwise applies structure-based AI (AtomNet) and partners with pharma on hit discovery; a relevant emerging peer in the virtual screening and AI-drug-discovery category overlapping with Schrödinger's Glide/DeepAutoQSAR workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/schr-dinger
• Instagraminstagram.com/schrodinger.inc
• Xx.com/schrodinger_inc
• Facebookfacebook.com/schrodingerco

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds9 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Schrödinger